Bayer hemophilia drug gets label expansion

The FDA approves Bayer's (BAYRY) Kogenate FS antihemophilic factor (recombinant) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A.

In the 84-patient SPINART study, patients under on-demand therapy experienced an average of 15.2x as many bleeds as those on the prophylactic regimen.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs